Pharmacologic inhibition of IRE1α-dependent decay protects alveolar epithelial identity and prevents pulmonary fibrosis in mice
Journal of Clinical Investigation · 2025
DOI: 10.1172/jci184522 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, 2025. Verfasst von Vincent C Auyeung und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pulmonary, Critical Care, Allergy, and Sleep Medicine. Hauptthemen laut MEDLINE: Endoribonucleases, Protein Serine-Threonine Kinases, Pulmonary Fibrosis, Alveolar Epithelial Cells. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 86 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS, NIDDK NIH HHS, NHLBI.
Abstract (Originalsprache)
Stress-induced epithelial plasticity is central to lung regeneration, fibrosis, and malignancy, but how cellular stress leads to differentiation is incompletely understood. Here, we found a central role for IRE1α, a conserved mediator of the unfolded protein response (UPR), in stimulating the plasticity of alveolar type 2 (AT2) cells. In single-cell RNA-seq, IRE1α activity was associated with loss of AT2 identity and progression toward a damage-associated transitional state unique to fibrosis. AT2 plasticity required destructive regulated IRE1α-dependent decay (RIDD), which we demonstrated by deploying PAIR2, a kinase modulator that inhibits RIDD while preserving IRE1α’s adaptive XBP1 mRNA splicing activity. In vivo, selective inhibition of RIDD with PAIR2 reduced AT2 differentiation into profibrotic transitional cells and protected mice from bleomycin-induced pulmonary fibrosis. Mechanistically, we identified the Fgfr2 mRNA as a direct and regulated substrate for IRE1α’s RNase in primary AT2 cells and in a biochemically reconstituted cell-free system. Loss of Fgf signaling caused AT2 differentiation, while gain of signaling protected cells from IRE1α-induced differentiation. We propose that IRE1α downregulates Fgf signaling through RIDD, provoking loss of AT2 identity and differentiation towards a profibrotic phenotype. Thus, IRE1α’s RIDD activity emerges as a novel target for treatment of pulmonary fibrosis and potentially other diseases driven by aberrant epithelial cell plasticity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Pulmonary, Critical Care, Allergy, and Sleep Medicine.
- Department of Medicine.
- Diabetes Center.
- Quantitative Biosciences Institute (QBI).
- Cardiovascular Research Institute.
- Division of Neonatology, Department of Pediatrics, UCSF, San Francisco, California, USA.
Förderung
- NHLBI NIH HHS
- NIDDK NIH HHS
- NHLBI
- American Lung Association
- Merck Research Laboratories
- NIDDK
Zitieren
APA
Auyeung, V. C., Steinberg, T. L., Olivier, A., Suzuki, L., Moreno, M. E., Khan, I. S., Downey, M. S., Thamsen, M., Guo, L., Maly, D. J., Backes, B. J., Sheppard, D., & Papa, F. R. (2025). Pharmacologic inhibition of IRE1α-dependent decay protects alveolar epithelial identity and prevents pulmonary fibrosis in mice. Journal of Clinical Investigation. https://doi.org/10.1172/jci184522
Vancouver
Auyeung VC, Steinberg TL, Olivier A, Suzuki L, Moreno ME, Khan IS, et al. Pharmacologic inhibition of IRE1α-dependent decay protects alveolar epithelial identity and prevents pulmonary fibrosis in mice. Journal of Clinical Investigation. 2025. doi:10.1172/jci184522
BibTeX
@article{Auyeung2025,
author = {Auyeung, Vincent C and Steinberg, Tavienne L and Olivier, Alina and Suzuki, Luka and Moreno, Mary E and Khan, Imran S and Downey, Michael S and Thamsen, Maike and Guo, Lu and Maly, Dustin J and Backes, Bradley J and Sheppard, Dean and Papa, Feroz R},
title = {Pharmacologic inhibition of IRE1α-dependent decay protects alveolar epithelial identity and prevents pulmonary fibrosis in mice},
journal = {Journal of Clinical Investigation},
year = {2025},
doi = {10.1172/jci184522}
}
EUVIMED